BioStock: BioInvent in new potentially lucrative license agreement

BioInvent has entered into an option and license agreement with American Exelixis with a focus on the identification and development of new antibodies for immuno-oncology treatments. The agreement gives Exelixis the right to select up to three immuno-oncology antibodies using Bioinvent’s proprietary F.I.R.S.T. platform and n-CoDeR library. Exelixis pays 25 million USD upfront, and, if they choose to in-license a candidate, a licensing deal is triggered that includes milestone payments and royalties.

Read the full article at biostock.se:

https://www.biostock.se/en/2022/06/bioinvent-in-new-potentially-lucrative-license-agreement/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/